Retatrutide

Retatrutide hits three receptors at once: GLP-1 and GIP — the two incretin pathways tirzepatide already targets — plus the glucagon receptor. The glucagon arm is the differentiator: glucagon-receptor activation raises energy expenditure and drives hepatic fat use, so the theory is that you add a "burn" lever on top of the appetite-suppression incretin levers. That third axis is also why the compound is watched closely on heart rate and glycemic control. Whether the triple mechanism is genuinely better than dual agonism, rather than just dosed higher, is exactly what the phase 3 program has to settle.

The headline phase 2 obesity trial (Jastreboff et al., 2023, NEJM) randomized adults with obesity across several doses; at 12 mg, mean weight reduction reached roughly 24% at 48 weeks versus placebo — the steepest curve published for any agent in this class to date, and it had not clearly plateaued. A parallel phase 2 trial in type 2 diabetes (Rosenstock et al., 2023, Lancet) showed strong HbA1c and weight reductions as well. Read these for what they are: randomized, double-blind, placebo-controlled — real evidence — but phase 2, dose-finding, a few hundred patients, under a year. The large phase 3 program (TRIUMPH) is what will decide whether the numbers hold and whether the safety profile is acceptable at scale. Calling retatrutide 'the strongest' on weight loss is fair; calling it established is not.

• Largest mean weight reduction reported in the class so far — ~24% at 12 mg over 48 weeks (phase 2)
• Substantial HbA1c reduction in type 2 diabetes (phase 2)
• Weight-loss curve had not plateaued by 48 weeks at the highest doses
• Improvements in lipids and blood pressure consistent with the degree of weight loss

• Not approved by any regulator — investigational, phase 2 only; long-term safety is unknown
• Dose-dependent GI effects (nausea, vomiting, diarrhea, constipation) are the most common adverse events
• Dose-dependent increases in heart rate were observed — a signal the glucagon-agonist mechanism makes worth watching
• As an incretin-class agent it carries the same theoretical thyroid C-cell concern flagged across GLP-1 drugs; trials monitor accordingly
• No phase 3 outcome or long-term safety data yet — efficacy numbers may shift in larger, longer trials
• Prescription-grade investigational drug — "research" sourcing outside a trial or licensed clinician is unsafe and outside any legal channel

In clinical trials. Under active investigation in human trials; not yet approved.

Goals studied: Fat loss, Body composition, Visceral fat reduction

Is retatrutide approved or available by prescription?

No. As of this writing retatrutide is investigational — it has completed phase 2 and is in phase 3 trials (the TRIUMPH program). It is not approved by the FDA or any other regulator and cannot be legally prescribed outside a clinical trial.

How does retatrutide differ from semaglutide and tirzepatide?

Semaglutide targets one receptor (GLP-1), tirzepatide targets two (GIP and GLP-1), and retatrutide adds a third — the glucagon receptor — which is thought to raise energy expenditure. Its phase 2 weight-loss numbers are the highest reported, but it is several years behind the approved drugs in evidence and regulatory status.

Are the ~24% weight-loss numbers reliable?

They come from a real randomized, placebo-controlled trial, so they are not hype — but they are phase 2 results in a few hundred people over 48 weeks. Phase 3 trials are larger, longer, and occasionally produce more modest numbers. Treat the figure as promising and provisional.

1. [1]
   Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial

   Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML · The New England Journal of Medicine · 2023 · PMID 37366315 · model: human

   Phase 2 RCT in adults with obesity where retatrutide produced dose-dependent weight loss reaching roughly 24% at the 12 mg dose over 48 weeks versus placebo.

2. [2]
   Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA

   Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T · Lancet · 2023 · PMID 37385280 · model: human

   Phase 2 RCT in type 2 diabetes showing retatrutide markedly lowered HbA1c and body weight versus placebo and an active comparator over the trial period.